Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The aging population has led to an increasing number of elderly patients with IgA nephropathy (IgAN). However, their clinical characteristics and renal prognosis remain poorly defined. This study aimed to clarify the clinical features and renal outcomes of elderly IgAN patients using data from a large Japanese prospective cohort.
Patients enrolled in the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS) were stratified by age into three categories: <40, 40–59, and ≥60 years. The primary composite outcome was defined as progression to end-stage kidney disease (ESKD) or a ≥30% decline in estimated glomerular filtration rate (eGFR). Kaplan–Meier and log-rank tests were used to assess renal survival, and Cox proportional hazards models identified predictors of adverse outcomes.
A total of 991 patients were included (median age 37.1 years [IQR 26.8–50.3]; 50.7% female). Median eGFR and proteinuria at baseline were 74.8 mL/min/1.73 m² (IQR 55.9–94.3) and 0.58 g/day (IQR 0.28–1.18), respectively. The numbers of patients in each age group were 555 (<40), 298 (40–59), and 138 (≥60). The corresponding numbers of primary outcome events were 41, 43, and 35. Elderly patients had lower baseline eGFR, higher proteinuria, and received fewer immunosuppressive therapies and tonsillectomies. The incidence of the primary outcome was significantly higher in the ≥60 group (P < 0.001). However, in multivariable analysis, age category itself was not an independent risk factor. Lower eGFR and higher proteinuria were associated with increased risk, whereas immunosuppressive therapy and tonsillectomy were linked to better renal survival. In subgroup analysis of elderly patients, those treated with immunosuppressive agents had significantly improved renal outcomes. Higher baseline eGFR and immunosuppressive treatment remained independent predictors of favorable prognosis.
Although elderly IgAN patients exhibit worse renal outcomes than younger ones, these differences appear largely attributable to baseline renal function and disease severity rather than chronological age. Immunosuppressive therapy may offer renal protection even in older adults. The content presented in this abstract was submitted for the IIgANN 2025. Re-submission has been permitted by the organizers of the original meeting.
